Hamlet BioPharma Releases Q3 Interim Report
Hamlet BioPharma AB has released its Q3 interim report for the period January–March 2026. The company also announced new patent allowances in May.
Hamlet BioPharma AB published its third-quarter interim report on May 22, 2026, covering the period from January to March 2026.
The company also announced progress on its patent portfolio. In a press release dated May 18, 2026, Hamlet BioPharma stated it had secured new patents and allowances related to its innovation and technology in the treatment of cancer and infections.
Hamlet BioPharma is a pharmaceutical company based in Lund, Sweden, focusing on a portfolio of projects aimed at developing treatments for cancer and infectious diseases.
The company holds regular investor meetings to discuss its financial results and project developments.